OncoMatch/Clinical Trials/NCT04712539

Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients

Is NCT04712539 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Baloxavir Marboxil and Oseltamivir for hematopoietic and lymphoid cell neoplasm.

Treatment: Baloxavir Marboxil · Oseltamivir — This phase II trial studies the effect of baloxavir in combination with oseltamivir in treating severe influenza infection in patients who have previously received a hematopoietic (blood) stem cell transplant or have a hematological malignancy. Baloxavir is an antiviral drug that inhibits the growth of influenza virus, reduces viral load and prevents further influenza infection. Osetamivir is an antiviral drug that blocks enzymes on the surfaces of influenza viruses, interfering with cell release of complete viral particles. Giving baloxavir in combination with oseltamivir may shorten or decrease the intensity of influenza infection compared to oseltamivir alone.